three
-
Alzheimer’s & Dementia Care
Anavex Life Sciences Reports Sustained Long-Term Benefits of Oral Blarcamesine in Early Alzheimer’s Disease Over Nearly Three Years
Copenhagen, Denmark – Anavex Life Sciences, a biopharmaceutical company focused on central nervous system disorders, has announced that the therapeutic…
Read More » -
Alzheimer’s & Dementia Care
Blarcamesine Demonstrates Sustained Efficacy Over Three Years in Early Alzheimer’s Disease, Offering Hope for Disease Modification
Copenhagen, Denmark – In a significant development for Alzheimer’s disease research, Anavex Life Sciences has announced that the therapeutic benefits…
Read More »
